IP Library Granted Patent US 11,944,807
Granted Patent B2
US 11,944,807 · App. 17/481,510 · Granted Apr 2, 2024

Vagal nerve stimulation for treating central nervous system disorders

Inventors: Bruce J. Simon (Mountain Lakes, NJ); Joseph P. Errico (Palm Beach Gardens, FL)
Assignee: Electrocore, Inc.
A61N1/0456A61N1/04A61N1/0492A61N1/0551A61N1/36014A61N1/36025A61N1/36034A61N1/0472A61N1/36017A61N1/36114A61N1/40A61N2/006A61N2/008A61N2/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,944,807
App. No.
17/481,510
Granted
Apr 2, 2024
Kind
B2
Abstract

Devices, systems and methods are disclosed for treating one or more symptoms of central nervous system disorders in a patient, such as anxiety disorders, fibromyalgia, traumatic brain injury, PTSD, and others. A method includes positioning a contact surface of a device in contact with an outer skin surface of patient and applying an electrical impulse transcutaneously from the device through the outer skin surface of the patient to a vagus nerve in the patient for about 90 seconds to about 3 minutes. The electrical impulse is sufficient to modify the vagus nerve such that the symptoms of the central nervous system disorder are reduced. For chronic treatment of such disorders, a stimulation protocol is provided that includes two or more doses administered per day for a period of time sufficient to relieve the symptoms.

Claims (17)

1. A method for treating symptoms of a central nervous system disorder in a patient, the method comprising:

positioning a contact surface of a device in contact with an anterior portion of an outer skin surface of a neck of a patient;

applying, via the device, when the contact surface is in contact with the outer skin surface of the patient, an electrical impulse transcutaneously from the device through the outer skin surface of the patient to a vagus nerve in the patient according to a stimulation protocol that includes at least two doses administered each day for a plurality of days; and

wherein the electrical impulse is sufficient to modify the vagus nerve such that the symptoms of the central nervous system disorder are reduced and wherein the electrical impulse comprises a burst period and a constant period, wherein each burst period comprises 2 to 20 pulses and wherein at least a portion of each constant period comprises zero pulses, wherein the burst period of each electrical impulse comprises sinusoidal waveforms which alternate between a positive and a negative electric field charge.

2. The method of claim 1 , wherein the device comprises one or more electrodes coupled to an energy source.

3. The method of claim 2 , further comprising attaching the one or more electrodes to the neck of the patient.

4. The method of claim 2 , wherein the device comprises a housing and the electrodes are part of the housing and wherein the energy source is housed within the housing.

5. The method of claim 1 , wherein the doses are separated by a time frame of about five to 15 minutes.

6. The method of claim 5 , wherein the stimulation protocol comprises 2 to 12 treatments/day.

7. The method of claim 1 , wherein the pulses have a frequency of about 1 kHz to about 20 kHz.

8. The method of claim 1 , wherein each burst period has a frequency of about 1 to about 100 bursts per second and each pulse has a duration of about 50 to about 1000 microseconds in duration.

9. The method of claim 1 , wherein the electrical impulse is sufficient to cause release of one or more types of inhibitory neurotransmitters in a brain of the patient.

10. The method of claim 9 , wherein the types of inhibitory neurotransmitters comprise one of GABA, serotonin, or norepinephrine.

11. The method of claim 1 , wherein the central nervous system disorder comprises fibromyalgia.

12. The method of claim 1 , wherein the central nervous system disorder comprises an anxiety disorder.

13. The method of claim 1 , wherein the central nervous system disorder comprises post-traumatic stress disorder (PTSD).

14. The method of claim 1 , wherein the central nervous system disorder comprises traumatic brain injury.

Assignments (2)
SECURITY INTEREST Recorded Aug 12, 2025
From: ELECTROCORE, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 072452/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: SIMON, BRUCE J.; ERRICO, JOSEPH P.
To: ELECTROCORE, INC.
Reel/Frame 057564/0487 →
Continuity (18)
Continuation 17346265 · Jun 13, 2021
Division 16693088 · Nov 22, 2019
Division 13952859 · Jul 29, 2013
Continuation In Part 13603781 · Sep 5, 2012
Continuation In Part 13222087 · Aug 31, 2011
Continuation In Part 13183765 · Jul 15, 2011
Continuation In Part 13183721 · Jul 15, 2011
Continuation In Part 13109250 · May 17, 2011
Continuation In Part 13075746 · Mar 30, 2011
Continuation In Part 13005005 · Jan 12, 2011
Continuation In Part 12964050 · Dec 9, 2010
Continuation In Part 12859568 · Aug 19, 2010
Provisional Application 61488208 · May 20, 2011
Provisional Application 61487439 · May 18, 2011
Provisional Application 61471405 · Apr 4, 2011
Provisional Application 61451259 · Mar 10, 2011
Provisional Application 61415469 · Nov 19, 2010
Related Publication 20220001166A1 · Jan 6, 2022
Cited By (1)
US 12,357,817